Catalyst Event

Pfizer Inc (PFE) · Other

From Akros U.S. High Dividend Index (AUHD20)

3/19/2026, 12:00:00 AM

OtherSentiment: Positive

Announced positive topline results from the Phase 3 TALAPRO-3 study of Talzenna in combination with Xtandi on March 19, 2026, which significantly improved radiographic progression-free survival in patients with metastatic prostate cancer; a high impact is estimated due to the significant clinical milestone.

Korean Translation

2026년 3월 19일, 전이성 전립선암 환자를 대상으로 한 탈제나(Talzenna)와 엑스탄디(Xtandi) 병용 요법의 3상 임상(TALAPRO-3)에서 방사선학적 무진행 생존기간을 유의미하게 개선했다는 긍정적인 탑라인 결과를 발표함.

Related Recent Events

View Full Timeline